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ABSTRACT 
Substances extracted from Cannabis varieties are of increasing interest, especially cannabidiol as a non-psychoactive 
drug with various pharmacological effects. Formulation of cannabidiol is, however, challenging due to its low water 
solubility. In this study, different types of lipid carriers were investigated as formulation options for cannabidiol to enable 
parenteral or oral application.  
The study included self-dispersing lipid formulations, nanoemulsions and liposomes. With regard to parenteral 
application, a higher load of cannabidiol was obtained in nanoemulsions than in liposomes. Lipid nanoemulsions are thus 
a very promising formulation option for parenteral formulations with a high drug load. Also in formulations intended for 
oral use a notably higher amount of cannabidiol could be incorporated in oil-containing self-dispersing formulations than 
in liposomes.  
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INTRODUCTION 
Cannabidiol (CBD) is a natural compound isolated from 
Cannabis varieties which has, unlike Δ9-
tetrahydrocannabinol, not shown psychoactive 
behaviour [Perez-Reyes, 1973]. Interest in CBD has 
increased since the beginning of the 2000s and several 
pharmacological effects are discussed, such as anti-
inflammatory, anti-oxidative and neuroprotective 
action. It is further suggested that CBD might be 
beneficial in diseases such as Parkinson’s disease, 
diabetes, nausea, cancer, inflammatory diseases and 
several others [Zuardi, 2008]. How to formulate 
cannabidiol is therefore an intriguing question in order 
to enable the use of this promising drug substance. 
Formulations in lipid carriers are especially promising 
options due to the lipophilicity of cannabidiol with 
regard to both parenteral and oral administration. Lipid 
carriers with sizes in the nanometer range can enable 
parenteral administration in the therapy with CBD 
which could be of interest due to the wide field of 
pharmacological effects. For oral therapy, self-
dispersing lipid formulations can be generated using 
phospholipids as natural emulsifier and solubilizer. 
These formulations can be filled into hard capsules and 
disperse in the gastro-intestinal fluids due to mild 
agitation. 
RESEARCH CONCEPT 
The maximum amount of drug loaded into dispersed 
formulations was determined by passive loading, a 
formulation screening method [Göke, 2017; Rosenblatt 
2017]. Using this method, the powdered drug is 
incubated with the respective carriers in aqueous media 
and loads into the dispersed carriers by diffusion. The 
excess of drug is removed from the dispersion by 
filtration and the amount of loaded drug is analyzed.  
For loading experiments with oral formulations, 5 % 
self-dispersing formulation (38 % medium chain 
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triglycerides (MCT), 57 % Phospholipon 90 G, 5 % 
ethanol 96 %) was dispersed in phosphate buffer pH 7.0. 
5 % Phospholipon 90 G was dispersed accordingly to 
generate liposomes for a comparison. The dispersions 
were then treated with an ultrasonic probe to reduce the 
particle sizes to around 200 nm. Centrifugation and 
subsequent filtration removed titanium particles of the 
probe and coarse materials from the dispersion. The 
phospholipid content was then determined by Stewart 
assay [Stewart, 1980] to check how much lipid was 
removed by these steps. Briefly, samples were dried 
under a flow of nitrogen at 40 °C and then dissolved in 
chloroform. Phospholipids were quantified by 
colorimetric reaction with ammonium ferrothiocyanate.  
Liposomes for parenteral formulations were produced 
by membrane extrusion. 10 % Lipoid S 75 was dispersed 
in phosphate buffer pH 7.4 and, after stirring overnight, 
ten times extruded through a 0.1 µm polycarbonate 
membrane to achieve a particle size of around 90 nm (all 
particle sizes were determined by photon correlation 
spectroscopy).  
Emulsions for parenteral application were produced by 
high-pressure homogenization. The production of the 
trimyristin emulsion was carried out at 75 °C, all other 
emulsions were produced at room temperature. Lipid 
(5 % trimyristin, 10 % MCT or 10 % soybean oil) and 
aqueous phase (poloxamer 188, sodium azide, water) 
were weighed in and dissolved separately. Afterwards 
the phases were united and processed by an ultra-turrax. 
These pre-emulsions were homogenized ten times in a 
Microfluidizer. The pressure applied depended on the 
formulation, resulting mean particle sizes were between 
110 nm and 280 nm.  
Lipofundin (5 % soybean oil, 5 % MCT, egg 
phospholipids) is a commercially available parenteral 
fat emulsion.     
Cannabidiol was added to the respective dispersion 
which was placed on a shaker. In case of oral 
formulations, samples were drawn in several intervals 
and analyzed for drug content by UV spectroscopy at 
215 nm (solute tetrahydrofuran/acetonitrile (8/2)) until 
saturation. Lipid carriers for parenteral application were 
incubated in independent vials and the drug content was 
analyzed by UV spectroscopy at 212 nm (solute 
tetrahydrofuran/water (9/1)). 
RESULTS 
Cannabidiol showed a remarkably high drug load in 
lipid formulations (up to approx. 47 % in relation to the 
lipid content (Fig. 1)). 
In formulations for oral application, CBD was loaded to 
a significantly higher extent into the self-dispersing 
mixture than into liposomes. In parenteral formulations, 
the trimyristin emulsion showed a considerably higher 
CBD load compared to emulsions of other oils. Drug 
loading into the phospholipid- and thus charge-
stabilized Lipofundin emulsion led to a comparable drug 
concentration as for a sterically(poloxamer)-stabilized 
MCT emulsion. In the same manner as for oral 
formulations, cannabidiol reached a much higher 
concentration in all emulsions as compared to 
liposomes.  
DISCUSSION 
The very high drug load in the trimyristin emulsion 
indicates a lipid dependence of achievable CBD load in 
emulsions. This is in agreement with literature reports, 
where lipid dependence is also shown for other drugs 
[Göke, 2017]. A comparable drug load in the differently 
stabilized Lipofundin and MCT emulsion implicates 
that there is no strict preference of CBD for sterically or 
charge-stabilized emulsions. Higher drug loading in 
emulsions and self-dispersing mixtures compared with 
liposomes emphasizes an advantage of oil-containing 
carrier systems for the formulation of CBD.  
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Fig. 1: Drug load of cannabidiol in parenteral 
formulations. 
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CONCLUSIONS 
Lipid nanoemulsions achieve a high load of cannabidiol 
and therefore enable parenteral administration. Due to 
the lipid-dependent drug loading, the choice of the lipid 
has to be taken into account upon formulation of CBD 
in nanoemulsions. Self-dispersing mixtures are a 
promising option as well, as they facilitate oral 
administration and can be loaded with high CBD 
concentrations, too. Liposomes are a less interesting 
option for CBD formulation as notably less drug 
substance loaded into these carriers.   
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